Abstract | BACKGROUND/OBJECTIVES: METHODS: Using a retrospective cohort analysis, we reviewed population data from International Medical Statistics (IMS) Health between November 2001 and October 2007. RESULTS: The total annual number of DMD prescriptions increased from 3.9, in 2002, to 5.1, in 2007, per 1,000 Canadians. The total annual cost of prescriptions rose from $187 million to $287 million. Of the four provinces responsible for the majority of prescriptions--Alberta, BC, Ontario, and Quebec--Quebec had the highest average annual prescription rate (7 per 1,000 population) and BC had the lowest rate (3.3 per 1,000 population). Subcutaneous interferon beta-1a was the most commonly used drug whereas glatiramer acetate showed the greatest growth in use from 2002 to 2007. CONCLUSIONS: Disease modifying drugs prescription rates and costs increased by more than 30% between 2002 and 2007. There was wide variation in DMD prescription rates and relative drug preferences across the provinces.
|
Authors | Dalia L Rotstein, Muhammad Mamdani, Paul W O'Connor |
Journal | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
(Can J Neurol Sci)
Vol. 37
Issue 3
Pg. 383-8
(May 2010)
ISSN: 0317-1671 [Print] England |
PMID | 20481274
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Canada
(epidemiology)
- Cohort Studies
- Disease Progression
- Drug Costs
(statistics & numerical data, trends)
- Drug Utilization
(economics, statistics & numerical data)
- Drug Utilization Review
(statistics & numerical data)
- Female
- Humans
- Immunologic Factors
(economics, therapeutic use)
- Male
- Multiple Sclerosis
(drug therapy, epidemiology)
- Retrospective Studies
|